Skip to contentO
Oric Pharmaceuticals, Inc.
O
ORICOric Pharmaceuticals, Inc. Released Nov 8, 2021, after the close
10-Q filed Nov 8, 2021, 39 days after period end · 0000950170-21-003477
Q3 2021 · 10-Q
Revenue—
Net Income-$18.43M-$18.43MN/M vs Q3 2020N/M vs Q2 2021 EPS Diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oric Pharmaceuticals, Inc. · CIK 1796280 · Engraved from SEC EDGAR
-$0.47-$0.47N/M vs Q3 2020N/M vs Q2 2021 Operating Income-$18,456,000N/M Operating Cash Flowderived-$12,142,000N/M Free Cash Flowderived-$12,375,000N/M ended Sep 30, 2021 · filed Nov 8, 2021 · 39 d after period end